The company in question is, Horizon Pharma plc (NASDAQ:HZNP) currently with a stock price of 17.6 (-1.79% today). The market cap for Horizon Pharma plc is 2918.81, and is in the sector Healthcare, and Drugs – Generic industry. The target price for Horizon Pharma plc is 31.33. Currently Horizon Pharma plc is trading with a P/E of *TBA, and a forward P/E of 6.61. Average volume for Horizon Pharma plc is 3623.02 and so far today it is 995702.
Performance in the last year for Horizon Pharma plc has been -3.71%. For EPS growth, Horizon Pharma plc has seen a growth of 108.10%, and is looking to grow in the next year to 26.18%. More long term stats show that EPS growth has been 15.00% over the last five years and could be 18.10% for the next five years. Horizon Pharma plc has seen sales growth quarter over quarter at 49.00%, with EPS growth quarter over quarter at -54.10%. The 20-day simple moving average is -10.82%, with the 200-day simple moving average coming to -1.27%.
Since the IPO date for Horizon Pharma plc on the 7/28/2011, Horizon Pharma plc has seen performance year to date to be -17.31%. With Horizon Pharma plc trading at 17.6, the dividend yield is *TBA, and the EPS is -0.03.
So could Horizon Pharma plc, be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 3.13 and the P/B is at 2.15. The P/cash is 6.88, with P/free cash flow at *TBA.
Horizon Pharma plc ability to deal with debt shows that the current ratio is 2.2, and the quick ratio is 1.8. This is with long term debt/equity at 0.85, and total debt/equity at 0.85.
In terms of margins, Horizon Pharma plc has a gross margin of 69.20%, an operating margin of 1.10% and a profit margin of -0.30%.Payout ratio for Horizon Pharma plc is *TBA. Return on assets come to -0.10% with return on investment coming to 3.00%.
Insider ownership for Horizon Pharma plc, is at 0.50% and institutional ownership comes to 89.60%. Outstanding shares are at 162.88. While shares float is 155.28. The float short is currently 11.03%, and short ratio is 4.73.